3SBioTRSBF -2.27%90 PB Ratio is 1.39 as of Jul. 07, 2026, which is 28% below its 10-year median of 1.94. GuruFocus rates TRSBF with a GF Score™ of 90/100 and a GF Value™ of $1.61 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,226 Biotechnology companies, 3SBio ranks better than 72.02% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), 3SBio's share price is $2.15. 3SBio's Book Value per Share for the quarter that ended in Dec. 2025 was $1.55. Hence, 3SBio's PB Ratio of today is 1.39.
The historical rank and industry rank for 3SBio's PB Ratio or its related term are showing as below:
TRSBF'
s PB Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.94 Max: 6.4
Current: 1.52
During the past 12 years, 3SBio's highest PB Ratio was 6.40. The lowest was 0.78. And the median was 1.94.
TRSBF's PB Ratio is ranked better than 72.02% of 1226
companies
in the Biotechnology industry
Industry Median: 2.91
vs TRSBF: 1.52
During the past 12 months, 3SBio's average Book Value Per Share Growth Rate was 71.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of 3SBio was 92.80% per year. The lowest was 5.60% per year. And the median was 13.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
3SBio PB Ratio Related Terms
3SBio PB Ratio Historical Data
* Premium members only.
The historical data trend for 3SBio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 3SBio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's PB Ratio distribution charts can be found below:
* The bar in red indicates where 3SBio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
3SBio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
3SBio (TRSBF) has a PB Ratio of 1.39 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 3SBio and its competitors. This is 28% below median its historical median of 1.94. Over the past decade, 3SBio's PB Ratio has ranged from 0.78 to 6.40. According to the industry distribution chart, 3SBio ranks #343 out of 1226 companies in the Biotechnology industry, placing it in the top 28%.
Is 3SBio's PB Ratio too high?
3SBio's current PB Ratio of 1.39 is 28% below median its 10-year median of 1.94. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 6.40. The Biotechnology industry median PB Ratio is 2.91. 3SBio's value of 1.39 is 52.2% below this industry median. Based on the distribution chart, 3SBio ranks #343 out of 1226 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3SBio has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #343 out of 1226 companies for PB Ratio. This puts 3SBio in the upper half of its industry. The industry median PB Ratio is 2.91. 3SBio's value of 1.39 is 52.2% below this benchmark. Historically, 3SBio's own PB Ratio has ranged from 0.78 to 6.40 over the past decade. While the company's 10-year median is 1.94 vs. the industry median of 2.91, 3SBio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current PB Ratio of 1.39 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current PB Ratio is 1.39, which is 28% below median its own 10-year median of 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (TRSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.61, compared to a current price of $2.15 — trading 33.5% above its estimated fair value. The current PB Ratio is 1.39, which is 28% below median its 10-year median of 1.94 and 52.2% below the Biotechnology industry median of 2.91. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For 3SBio (TRSBF), the current PB Ratio is 1.39 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (TRSBF) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of $2.15 is trading 33.5% above its estimated GF Value™ of $1.61.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for TRSBF:
PB Ratio: 1.39 (28% below median its 10-year median of 1.94)
GF Value™: $1.61 vs. price of $2.15 (33.5% above fair value)
Industry Position: 52.2% below the Biotechnology median (#343 of 1226)
No single metric tells the full story. See the TRSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for TRSBF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRSBF has been successfully added to your 
